Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.44 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | CHEK2 | O96017 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12106572 | 0.94 | PARP1 (0.44) | HDAC4PARP1CHEK1CHEK2FLT3 | |
| SCHEMBL1300626 | 0.91 | PARP1 (0.46) | HDAC4PARP1CHEK1CHEK2MAPT | |
| SCHEMBL1300817 | 0.91 | MAPT (0.50) | HDAC4PARP1CHEK2MAPTNPSR1 | |
| SCHEMBL1301024 | 0.91 | PARP1 (0.47) | HDAC4PARP1CHEK1CHEK2FLT3 | |
| SCHEMBL13849189 | 0.80 | ENPP2 (0.48) | CHEK1FLT3MAPTNPSR1KMT2A | |
| SCHEMBL13849193 | 0.78 | FLT3 (0.52) | CHEK1FLT3 | |
| SCHEMBL31172327 | 0.77 | FLT3 (0.56) | CHEK1CHEK2FLT3 | |
| SCHEMBL13849215 | 0.76 | FLT3 (0.48) | PARP1CHEK1CHEK2FLT3 | |
| SCHEMBL13849212 | 0.76 | FLT3 (0.48) | TOP2ACHEK1FLT3 | |
| SCHEMBL13849192 | 0.75 | FLT3 (0.46) | CHEK1FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-11542492-B2 | Ligand-directed covalent modification of protein | CELGENE CAR LLC (BM) | 2023-01-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | CELGENE CAR LLC (BM) | 2017-08-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | CELGENE CAR LLC (BM) | 2011-11-03 | — | — | US | disclosed |
| WO-2011082285-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | AVILA THERAPEUTICS, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542492-B2 | Ligand-directed covalent modification of protein | PTMS, SPR, DNPEP | HDAC4 1449/4885TOP2A 3219/4885PARP1 1989/4885 |
| US-20110269244-A1 | LIGAND-DIRECTED COVALENT MODIFICATION OF PROTEIN | PTMS, SPR, DNPEP | HDAC4 1449/4885TOP2A 3219/4885PARP1 1989/4885 |
| US-20170218353-A1 | Ligand-Directed Covalent Modification of Protein | PTMS, SPR, DNPEP | HDAC4 1449/4885TOP2A 3219/4885PARP1 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.